Neoadjuvant PD-1 Blockade in Early-stage Mismatch Repair-deficient Cancers Can Eliminate the Need for Surgery Regardless of Tumor Type
April 27, 2025
April 27, 2025
PHILADELPHIA, Pennsylvania, April 27 [Category: Medical] -- The American Association for Cancer Research posted the following news release:
* * *
Neoadjuvant PD-1 Blockade in Early-stage Mismatch Repair-deficient Cancers Can Eliminate the Need for Surgery Regardless of Tumor Type
CHICAGO - PD-1 blockade with dostarlimab (Jemperli) induced complete tumor clearance and resolved the need for surgery in patients with locally advanced, mismatch repair-deficient . . .
* * *
Neoadjuvant PD-1 Blockade in Early-stage Mismatch Repair-deficient Cancers Can Eliminate the Need for Surgery Regardless of Tumor Type
CHICAGO - PD-1 blockade with dostarlimab (Jemperli) induced complete tumor clearance and resolved the need for surgery in patients with locally advanced, mismatch repair-deficient . . .